by Portfolio Grader | January 15, 2014 12:30 pm
The grades of nine biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
Pharmacyclics, Inc. (PCYC) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. In Portfolio Grader’s specific subcategories of Equity and Sales Growth, PCYC also gets A’s. The stock price has risen 21.9% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of PCYC stock.
The rating of Neurocrine Biosciences, Inc. (NBIX) moves up this week, rising from a C to a B. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. For more information, get Portfolio Grader’s complete analysis of NBIX stock.
Medivation, Inc.’s (MDVN) ratings are looking better this week, moving up to a B from last week’s C. Medivation acquires, develops, and sells or partners biomedical technologies in the early development stage of the research and development process. For more information, get Portfolio Grader’s complete analysis of MDVN stock.
This week, Biogen Idec (BIIB) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Biogen Idec is a global biotechnology company that meets the needs of therapeutic care providers and recipients. For more information, get Portfolio Grader’s complete analysis of BIIB stock.
This is a strong week for Emergent BioSolutions Inc. (EBS). The company’s rating climbs to B from the previous week’s C. Emergent BioSolutions develops and produces immunobiotics, pharmaceutical products that assist the body’s immune system to prevent or treat disease. For more information, get Portfolio Grader’s complete analysis of EBS stock.
InterMune, Inc. (ITMN) shows solid improvement this week. The company’s rating rises from a C to a B. InterMune is a biotechnology company. For more information, get Portfolio Grader’s complete analysis of ITMN stock.
Insmed Incorporated (INSM) earns an A this week, jumping up from last week’s grade of B. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. For more information, get Portfolio Grader’s complete analysis of INSM stock.
This week, Hyperion Therapeutics, Inc.’s (HPTX) ratings are up from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of HPTX stock.
This week, XOMA Corporation (XOMA) pushes up from a C to a B rating. XOMA engages in the discovery and development of antibody-based therapeutics in the United States, Europe, and the Asia Pacific. For more information, get Portfolio Grader’s complete analysis of XOMA stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2014/01/9-biotechnology-stocks-to-buy-now-pcyc-nbix-mdvn/
Short URL: http://invstplc.com/1hTOdLf
Copyright ©2016 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.